The Adaptive Experience
The time from Clonality (ID) test to first Tracking MRD test can span a longer time frame for patients with myeloma.
For how long are patients with myeloma monitored with clonoSEQ?
Initiation of clonoSEQ MRD testing will vary based on a patient’s presentation and treatment course. For approximately half of myeloma patients, the first MRD will be evaluated within a year of diagnosis*. The timeframe for initiation of MRD for patients with myeloma may span a wider range of several years from the time of diagnosis. *Assumes ID collection date is indicative of time of diagnosis
Years after diagnosis that HCPs initiate clonoSEQ MRD Testing in MM
This page is intended for use by healthcare professionals of the United States.
clonoSEQ® is available as a FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies to detect minimal residual disease (MRD) in bone marrow samples from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) , and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers as a CLIA-validated laboratory developed test (LDT) service. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technicalsummary.